Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Jennerex/Lee’s Pharma Report Positive Phase II Data for Cancer Drug

publication date: Nov 8, 2011
Jennerex, a San Francisco clinical-stage biotech focused on cancer therapies, released positive data on its novel treatment for liver cancer, JX-594. Lee’s Pharma of Hong Kong has in-licensed China rights to the drug, and will conduct the China portion of a global Phase III trial. About 600,000 cases of hepatocellular carcinoma are diagnosed each year, of which 350,000 are in China. The US reports only 20,000 new cases every year. More details....

Stock Symbol: (HK: 8221)     Share this with colleagues:  

 


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital